Stem definition | Drug id | CAS RN |
---|---|---|
1312 | 70-18-8 |
None
None
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hepatic function abnormal | 45.82 | 27.52 | 17 | 579 | 34404 | 46651062 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Lymphocyte count decreased | 66.38 | 30.42 | 24 | 882 | 19031 | 29932541 |
Neutrophil count increased | 59.78 | 30.42 | 21 | 885 | 15302 | 29936270 |
Incision site pain | 51.60 | 30.42 | 12 | 894 | 1992 | 29949580 |
Hepatic function abnormal | 51.10 | 30.42 | 25 | 881 | 41920 | 29909652 |
Red blood cells urine positive | 32.86 | 30.42 | 8 | 898 | 1609 | 29949963 |
Source | Code | Description |
---|---|---|
ATC | V03AB32 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes |
CHEBI has role | CHEBI:22586 | antioxidants |
CHEBI has role | CHEBI:23357 | cofactor |
CHEBI has role | CHEBI:75771 | mus musculus metabolite |
CHEBI has role | CHEBI:76971 | e.coli metabolites |
CHEBI has role | CHEBI:77746 | h. sapiens metabolites |
CHEBI has role | CHEBI:85046 | melanogenesis inhibitors |
CHEBI has role | CHEBI:75772 | baker's yeast metabolite |
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 1.97 | acidic |
pKa2 | 3.3 | acidic |
pKa3 | 9.09 | acidic |
pKa4 | 11.82 | acidic |
pKa5 | 13.85 | acidic |
pKa6 | 9.79 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Glutathione S-transferase kappa 1 | Enzyme | IC50 | 7.70 | CHEMBL |
ID | Source |
---|---|
4020562 | VUID |
N0000148266 | NUI |
D00014 | KEGG_DRUG |
4020562 | VANDF |
C0017817 | UMLSCUI |
CHEBI:16856 | CHEBI |
GSH | PDB_CHEM_ID |
CHEMBL1543 | ChEMBL_ID |
DB00143 | DRUGBANK_ID |
D005978 | MESH_DESCRIPTOR_UI |
124886 | PUBCHEM_CID |
6737 | IUPHAR_LIGAND_ID |
GAN16C9B8O | UNII |
4890 | RXNORM |
NOCODE | MMSL |
003447 | NDDF |
423272009 | SNOMEDCT_US |
55477000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Bio-7 Serum | HUMAN OTC DRUG LABEL | 2 | 71583-1002 | LIQUID | 3 g | TOPICAL | unapproved drug other | 7 sections |
Bio-7 | HUMAN OTC DRUG LABEL | 2 | 71583-1003 | CREAM | 3.26 g | TOPICAL | unapproved drug other | 7 sections |
Vista Advanced AREDS2 Formula | HUMAN OTC DRUG LABEL | 7 | 77790-009 | CAPSULE | 25 mg | ORAL | unapproved drug other | 11 sections |
HARUTO HANGOVER DEFENCEPATCH | HUMAN OTC DRUG LABEL | 1 | 80094-0001 | PATCH | 1.42 mg | TOPICAL | unapproved drug other | 7 sections |